Translational Development Acquisition Corp.

Translational Development Acquisition Corp., trading under the ticker TDAC, is a blank-check company focused on the life sciences and healthcare sector, with its name reflecting an orientation toward translational medicine and biopharmaceutical development. The company filed a Form 425 communication with the SEC on July 27, 2026, under accession number 0001104659-26-087089, a filing type associated with business combination transactions, indicating TDAC is actively engaged in a de-SPAC merger process. Form 425 filings are prospectus-related communications submitted in connection with announced combination agreements. Full sponsor details, deal terms, and historical filing records for TDAC are available on SpacDesk — sign up at SpacDesk.com for comprehensive SPAC data and real-time transaction tracking.